OBJECTIVE: The prevalence of diabetes mellitus (DM) is steadily rising in the U.S., both in the general population and among those with cardiovascular disease (CVD). Understanding how to treat a patient with both conditions is becoming increasingly important. With multiple therapeutic options for CVD management, some medications will invariably impact glycemia in this group of patients. The concept of "DM-friendly" management of CVD is based on a treatment approach of selecting medications that do not impair glycemic control and provide equivalent cardioprotective effects. This article reviews the glycemic effects of various classes of medications commonly used to treat CVD. METHODS: Data sources were all PubMed- and Google Scholar-referenced articles in English-language peer-reviewed journals from 1980 through April 2016. Studies selected could include observational studies or prospective clinical trials. Prospective clinical trials included in this review focused on investigating the association of the medication of interest with glycemic outcomes. Meta-analyses and systematic reviews were also included. RESULTS: The data on glycemic effects were lacking for many of the medication classes and individual medications examined. However, in our review, certain beta-blockers and renin angiotensin aldosterone system inhibitors, and select calcium channel blockers were consistently shown to have favorable glycometabolic profiles when compared with other commonly used cardiovascular therapies. CONCLUSION: Several commonly prescribed medications for the treatment of CVD, such as certain beta-blockers and renin angiotensin aldosterone system inhibiting agents, are associated with favorable glycometabolic effects. As clinicians are more often faced with the challenge of treating patients with DM and concomitant CVD, consideration of how common cardiovascular medications may affect glycemia should be incorporated into the clinical decision making process. ABBREVIATIONS: A1C = hemoglobin A1C ACE = angiotensin-converting enzyme ARB = angiotensin II receptor blocker CCB = calcium channel blocker CI = confidence interval CVD = cardiovascular disease DM = diabetes mellitus MI = myocardial infarction RR = relative risk.
OBJECTIVE: The prevalence of diabetes mellitus (DM) is steadily rising in the U.S., both in the general population and among those with cardiovascular disease (CVD). Understanding how to treat a patient with both conditions is becoming increasingly important. With multiple therapeutic options for CVD management, some medications will invariably impact glycemia in this group of patients. The concept of "DM-friendly" management of CVD is based on a treatment approach of selecting medications that do not impair glycemic control and provide equivalent cardioprotective effects. This article reviews the glycemic effects of various classes of medications commonly used to treat CVD. METHODS: Data sources were all PubMed- and Google Scholar-referenced articles in English-language peer-reviewed journals from 1980 through April 2016. Studies selected could include observational studies or prospective clinical trials. Prospective clinical trials included in this review focused on investigating the association of the medication of interest with glycemic outcomes. Meta-analyses and systematic reviews were also included. RESULTS: The data on glycemic effects were lacking for many of the medication classes and individual medications examined. However, in our review, certain beta-blockers and renin angiotensin aldosterone system inhibitors, and select calcium channel blockers were consistently shown to have favorable glycometabolic profiles when compared with other commonly used cardiovascular therapies. CONCLUSION: Several commonly prescribed medications for the treatment of CVD, such as certain beta-blockers and renin angiotensin aldosterone system inhibiting agents, are associated with favorable glycometabolic effects. As clinicians are more often faced with the challenge of treating patients with DM and concomitant CVD, consideration of how common cardiovascular medications may affect glycemia should be incorporated into the clinical decision making process. ABBREVIATIONS: A1C = hemoglobin A1CACE = angiotensin-converting enzyme ARB = angiotensin II receptor blocker CCB = calcium channel blocker CI = confidence interval CVD = cardiovascular diseaseDM = diabetes mellitus MI = myocardial infarction RR = relative risk.
Authors: Veena Rajanna; Kristen B Campbell; Jeffrey Leimberger; Bibhu D Mohanty; John R Guyton Journal: J Clin Lipidol Date: 2011-12-23 Impact factor: 4.766
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: Amit P Amin; Alok Bachuwar; Kimberly J Reid; Adnan K Chhatriwalla; Adam C Salisbury; Robert W Yeh; Mikhail Kosiborod; Tracy Y Wang; Karen P Alexander; Kensey Gosch; David J Cohen; John A Spertus; Richard G Bach Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094
Authors: Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto Journal: J Am Soc Nephrol Date: 2009-11-19 Impact factor: 10.121
Authors: Byung-Hee Oh; Jerry Mitchell; James R Herron; Jenny Chung; Mahmudul Khan; Deborah L Keefe Journal: J Am Coll Cardiol Date: 2007-03-20 Impact factor: 24.094
Authors: Elisabetta Galai; Lorenza Scotti; Marco Gilardetti; Andrealuna Ucciero; Daniela Ferrante; Elisabetta Poluzzi; Armando A Genazzani; Francesco Barone-Adesi Journal: Int J Environ Res Public Health Date: 2022-06-15 Impact factor: 4.614
Authors: Kylie E Adamek; Deepa Ramadurai; Elise Gunzburger; Mary E Plomondon; P Michael Ho; Sridharan Raghavan Journal: J Am Heart Assoc Date: 2019-02-05 Impact factor: 5.501